The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
Open accessAbstract
Introduction Immune checkpoint inhibitors (ICIs) are standard therapies in advanced NSCLC. Although genotype-directed tyrosine kinase inhibitors represent the standard of care for subsets of oncogene-driven NSCLC, patients may receive ICIs during their disease course. The impact of sequential ICI and tyrosine kinase inhibitor therapy on the risk of hepatotoxicity has not been described.Methods Patients with advanced ALK receptor tyrosine kinase (ALK)-driven, ROS1-driven, or MET proto-oncogene, receptor tyrosine kinase (MET)-driven NSCLC treated with crizotinib, with or without preceding ICI therapy, were identified. The cumulative incidences of crizotinib-associated grade 3 or higher increases in transaminase level (per the Common Terminology Criteria for Adverse Events, version 4.0) were compared.Results We identified 453 patients who had NSCLC with an oncogenic alteration in ALK receptor tyrosine kinase gene (ALK), ROS1, or MET proto-oncogene, receptor tyrosine kinase gene (MET) and were treated with crizotinib (11 with and 442 without prior ICI therapy). Among the 11 patients treated with an ICI followed by crizotinib, five (cumulative incidence 45.5% [95% confidence interval (CI): 14.9-72.2]) experienced development of a grade 3 or 4 increase in alanine transaminase level and four (cumulative incidence 36.4% [95% CI: 10.0-64.2]) experienced development of a grade 3 or 4 increase in aspartate transaminase level. In comparison, among the 442 patients who received crizotinib only, a grade 3 or 4 increase in alanine transaminase level occurred in 34 patients (cumulative incidence 8.1% [95% CI: 5.7-11.0, p < 0.0001]) and a grade 3 or 4 increase in aspartate transaminase level occurred in 14 (cumulative incidence 3.4% [95% CI: 1.9-5.5, p < 0.0001]). There were no grade 5 transaminitis events. All cases of hepatotoxicity after sequential ICI and crizotinib use were reversible and nonfatal, and no case met the Hy's law criteria.Conclusions Sequential ICI and crizotinib treatment is associated with a significantly increased risk of hepatotoxicity. Careful consideration and monitoring for hepatotoxicity may be warranted in patients treated with crizotinib after ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the timing and sequence of combination therapy also influence treatment toxicity, which should be further validated in clinical studies [186, 207].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [207]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 and its ligand programmed death ligand 1 (PD-L1) have entered the clinic across multiple solid tumors, including NSCLC.1 On the basis of KEYNOTE-189, pembrolizumab plus platinum-doublet chemotherapy is the standard first-line treatment for nonsquamo…”
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Self-citationCamidge, D. R., Bang, Y., Kwak, E. L., Iafrate, A. J., Varella‐Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. I., Kim, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,267
Self-citationLisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580
Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313 · cited 1×
“In one observational study, the risk of EGFR TKI–associated pneumonitis was substantially higher with sequential or concurrent ICI and TKI therapy, although other toxicities were not investigated.(4) In a separate phase II study of pembrolizumab in TKI-naive EGFR-mutant NSCLC, two of seven patients subsequently treate…”
Spigel, D. R., Reynolds, C., Waterhouse, D., Garon, E. B., Chandler, J., Babu, S., Thurmes, P., Spira, A., Jotte, R., Zhu, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.022 · Cited by 229 · cited 1×
“For example, a phase 1/2 study of nivolumab plus crizotinib in ALK-rearranged NSCLC was terminated early because of severe hepatotoxicity in five of 13 patients (38%).(6) Two patients died, highlighting the importance of diagnosing and intervening on potentially fatal hepatotoxicity.”
Gibbons, D. L., Chow, L. Q. M., Kim, D.-W., Kim, S., Yeh, T. C., Song, X., Jiang, H., Taylor, R., Karakunnel, J. J., & Creelan, B. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30171-x · Cited by 112
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., McLeod, D., & Hirsh, V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8049 · Cited by 81
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–140 of 140
Choi, S.-J., Lee, J. B., Kim, J. H., Hong, M. H., Cho, B. C., & Lim, S. M. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241240657 · Cited by 2
Global research trends on ALK-TKIs in non-small cell lung cancer: a bibliometric analysis
Liu, Y., Han, Z., Li, Y., Zhang, P., & Wang, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1665174 · Cited by 1
Yin, H., Wang, X., Wang, Z., Wang, Z., Lv, X., Jiang, L., Cao, J., & Liu, Y. (2026) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6c00032 · Cited by 1
Husseini, K. E., & Wislez, M. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2021.100820 · Cited by 1
Wu, S., Chiang, C., Wang, C., Hung, J., Hsia, T., Kuo, C. S., & Shih, J. (2022) · Journal of Cancer · doi:10.7150/jca.74617 · Cited by 1
“Sequential ICI and ALK-TKI (crizotinib) treatment was associated with a significantly increased risk of hepatotoxicity in patients with ALK, ROS1, or MNNG HOS transforming gene (MET) exon 14 alterations [32].”
BackgroundZhu, Y., Yang, Y., Liu, Y., Qian, H., Qu, G., Shi, W., & Liu, J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05176-1 · Cited by 1
“In recent years, the advent of immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer by targeting immune checkpoints (Lin et al. 2019).”
BackgroundZarogoulidis, P., Matthaios, D., Oikonomou, P., Nikolaou, C., Charalampidis, C., & Sardeli, C. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100757 · Cited by 1
Conci, N., Marchiori, V., Federico, A. D., Giglio, A. D., Sperandi, F., Melotti, B., & Gelsomino, F. (2024) · Personalized Medicine · doi:10.1080/17410541.2024.2369493 · Cited by 1
Hyper–Sensitive? Targeted Therapy With a Primed Immune System
Rittberg, R., Abraham, N., Laskin, J. J., & Ho, C. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.003 · Cited by 1
Chour, A., & Duruisseaux, M. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.021 · Cited by 1
Cytryn, S. L., Ferreira, V. C. D., Boland, P. M., Chachoua, A., & Sabari, J. K. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.033
(2019) · Reactions Weekly · doi:10.1007/s40278-019-57135-7
[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].
Zheng, Y., Jiang, W., Li, J., Dai, L., Chen, D., Li, Y., Huang, L., & Wang, M. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.32
Crizotinib Restored Pembrolizumab Response in Advanced Non-Small Cell Lung Cancer
(2022) · European Journal of Respiratory Medicine · doi:10.31488/ejrm.126
Ohno, H., Hayashi, T., Torii, S., Niwa, M., Katagiri, N., Nakao, Y., Mano, S., Takimoto, N., & Hirashita, T. (2024) · Cancers · doi:10.3390/cancers16112076
“Other relevant findings reported include an increased risk of hepatotox-icity associated with crizotinib administered after ICI therapy [27].”
BackgroundFrom Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC
Liu, H. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/0trsfx05
“Also, available evidence supports the idea that EGFR-TKIs could also be contributing to combinations as they increase disease-free survival or adjuvant treatment for early resected NSCLC patients in the form of doublets [40, 41].”
Li, M., Yue, Z., Wang, M., Wāng, Y., Xiao, P., Wei, Y., Shen, J.-D., & Li, Y. (2025) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2536058
“…is well documented, growing clinical evidence and preclinical studies have reported its potential to cause hepatotoxicity (Jung et al. 2018; lin et al. 2019; Guo et al. 2022). according to pharmacovigilance data and case reports, the incidence of crizotinib-induced liver injury ranges from…”
D’Souza, A. D., & Ahn, R. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_10
Molecular Therapy and Targeted Treatment for Cancer (with Surgical Lenses)
Florez, N., Sridhar, A., Kiel, L., Morabito, A. S., Kaufman, R., & Olazagasti, C. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.07.008
Liu, R., Liu, H., Chen, H., An, K., Wei, J., Zhang, J., Du, Y., Wang, Y., & Tian, X. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf154
Biomarker-Directed Precision Medicine for Lung Cancer Control
Desai, P. A., & Borghaei, H. (2025) · Springer eBooks · doi:10.1007/978-3-032-02200-4_14
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666014
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666002
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666011
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24979480
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26665999
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666005
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24980072
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666008
Luo, X., Du, X., Chen, Q., Wang, C., Li, L., He, X., Gong, Y., Chen, J., Zhong, X., Liu, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2025.114613
“26 In addition, genetic susceptibility, such as the STAT1 rs10208033 polymorphism, has also been implicated in crizotinib-related liver injury.”
Mechanisms and management of crizotinib-induced toxicity in non-small cell lung cancer
Liu, X., Tao, X., Cheng, M., Yan, H., Xu, Z., Yang, B., He, Q., Luo, P., Yan, F., & Du, J. (2026) · Toxicology Letters · doi:10.1016/j.toxlet.2026.111846
Brage, S. E., Svedman, F. C., Bergqvist, M., & Helgadóttir, H. (2026) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2026.101595
“21 By combining ICI with a more selective MET inhibitor than crizotinib, which is a broad tyrosine kinase receptor inhibitor, it may offer better tolerability.”
Chen, C., Wang, Y., ZHAO, Y., Cao, W., Chen, A., Liu, X., Shi, Z., & Shen, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1756928 · Cited by 1
“Similarly, Lin and colleagues found that NSCLC patients administered ICI before TKI might lead to increased hepatotoxicity (32).”
Miyajima, Y., Kawakami, T., Notsu, A., Fushiki, K., Oshima, K., Ohba, A., Tsushima, T., Hamauchi, S., Yokota, T., Onozawa, Y., et al. (2026) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyag073
Contemporary Lung Cancer Nodal Staging and Therapeutic Decision-Making in the 9th TNM Era
Nakajima, T., & Eapen, G. A. (2026) · Cancers · doi:10.3390/cancers18132071
“In particular, sequential exposure to ICIs followed by targeted therapies such as EGFR-TKIs or ALK-TKIs may increase the risk of potentially fatal interstitial pneumonitis [35] and severe hepatotoxicity [36], likely owing to sustained immune activation and prolonged receptor occupancy.”
Targeting Oncogenic Gene Fusions in Lung Cancer
Nie, Y., & Wilson, F. H. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000837
Pierret, T., Auliac, J. B., Ricordel, C., Daniel, C., Nguyen, J., Guisier, F., Swalduz, A., Curcio, H., Désage, A.-L., Bigay-Game, L., et al. (2026) · Current Oncology · doi:10.3390/curroncol33090510
“That observation was also shown for crizotinib, with a median interval of 30 days for grade 3/4 aspartate aminotransferase/alanine aminotransferase elevation, compared to 50 days for patients without elevated transaminases [19].”
The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective
Waissengrin, B., Tagliamento, M., Sankar, K. N., & Reckamp, K. L. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103957
Chen, J.-M., Kang, Y.-F., Zeng, Y.-C., Luo, J., Lin, S., & Tang, W.-J. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.09.002
Metadata
- Authors
- Lin, J. J., Chin, E., Yeap, B. Y., Ferris, L. A., Kamesan, V., Lennes, I. T., Sequist, L. V., Heist, R. S., Mino-Kenudson, M., Gainor, J. F., & Shaw, A. T.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Shaw, Alice T.
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 14
- Issue
- 1
- Pages
- 135-140
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC6309637
- OpenAlex
- W2890230728
- Cited by
- 140
- References
- 15
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 24 · 2023: 24 · 2022: 16 · 2021: 15 · 2020: 24 · 2019: 5
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Massachusetts General Hospital
- National Cancer Institute (R01CA164273)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- immune checkpoint inhibitors, crizotinib, non-small cell lung cancer, anaplastic lymphoma kinase, ROS1, MET, tyrosine kinase inhibitors, sequential therapy, drug-drug interactions, transaminase elevation, liver injury, adverse drug reactions, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Crizotinib, Proto-Oncogene Mas, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
